| 31.05 08:17 | dpa-AFX: *SANOFI BEI TG WIEDER -0,9% NACH VORTAGESERHOLUNG - TROTZ GUTER DUPIXENT-NEWS |
| 31.05 08:10 | US-Prüfung für Sanofi-Arznei Dupixent um drei Monate verlängert |
| 31.05 07:29 | dpa-AFX: Sanofi, Regeneron: Dupixent Recommended For EU Approval By CHMP To Treat COPD Patients |
| 31.05 07:19 | dpa-AFX: Regeneron : FDA Extends Review Period For Dupixent As COPD Treatment By Three Month |
| 31.05 07:09 | dpa-AFX: *SANOFI: EUROPEAN MEDICINES AGENCY'S CHMP ADOPTS POSITIVE OPINION RECOMMENDING HE APPROVAL OF DUPIXENT IN EU |
| 31.05 07:05 | dpa-AFX: GNW-Adhoc: Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD |
| 30.05 15:01 | dpa-AFX: GNW-Adhoc: Press Release: Sanofi completes acquisition of Inhibrx, Inc. |
| 27.05 07:24 | dpa-AFX: Sanofi's Sarclisa Granted FDA Priority Review For Transplant-Ineligible Multiple Myeloma Treatment |
| 27.05 07:00 | dpa-AFX: GNW-Adhoc: Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma |
| 21.05 11:20 | dpa-AFX: Sanofi, OpenAI To Build AI Software To Boost Drug Development |
| 21.05 08:01 | dpa-AFX: Sanofi, Formation Bio, OpenAI Announce AI Collaboration |
| 21.05 07:51 | dpa-AFX: *SANOFI, FORMATION BIO, OPENAI COLLABORATE ON AI DRUG DEVELOPMENT ACCELERATION |
| 21.05 07:30 | dpa-AFX: GNW-Adhoc: Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration |
| 20.05 20:15 | dpa-AFX: GNW-Adhoc: Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM |
| 14.05 02:41 | dpa-AFX: *SIEMENS AND SONY PARTNER TO BRING NX IMMERSIVE DESIGNER, INCLUDING SONY'S XR HEAD-MOUNTED DISPLAY |
| 13.05 12:37 | FDA prüft Antrag von Regeneron und Sanofi für Dupixent vorrangig |
| 13.05 12:33 | dpa-AFX: Fulcrum Therapeutics Stock Climbs In Pre-market On License Deal With Sanofi For Losmapimod |
| 13.05 12:23 | dpa-AFX: ANALYSE-FLASH: Deutsche Bank Research belässt Sanofi auf 'Sell' - Ziel 80 Euro |
| 13.05 12:23 | dpa-AFX: Deutsche Bank Research belässt Sanofi auf 'Sell' - Ziel 80 Euro |
| 13.05 12:15 | dpa-AFX: *FULCRUM THERAPEUTICS ENTERS LICENSE DEAL WITH SANOFI FOR DEVELOPMENT OF LOSMAPIMOD IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
|
|
